Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma

(2012) Torsten Steinbrunn et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide enhances anti-myeloma cellular immunity

(2012) Katarina Luptakova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

(2012) Nicole Hassold et al.   INTERNATIONAL JOURNAL OF CANCER

The role of natural killer cells in immunity against multiple myeloma

(2012) James Godfrey et al.   LEUKEMIA & LYMPHOMA

Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma

(2011) Edvan de Queiroz Crusoe et al.   ANNALS OF HEMATOLOGY

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

(2011) D. M. Benson et al.   BLOOD

Lenalidomide

(2011) Lesley J. Scott et al.   DRUGS

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

(2011) A Kreutzman et al.   LEUKEMIA

Integration of Activating and Inhibitory Receptor Signaling by Regulated Phosphorylation of Vav1 in Immune Cells

(2011) S. Mesecke et al.   Science Signaling

TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms

(2011) H Rauert et al.   Cell Death & Disease

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma

(2010) I. H. Gabriel et al.   BLOOD

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

(2010) A. K. Hsu et al.   BLOOD

Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585

(2010) Thorsten Stühmer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Drug-mediated and cellular immunotherapy in multiple myeloma

(2010) David S Ritchie et al.   Immunotherapy

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

(2009) M Lioznov et al.   BONE MARROW TRANSPLANTATION

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

(2009) Maria Berg et al.   CYTOTHERAPY

Following TRAIL’s path in the immune system

(2009) Christina Falschlehner et al.   IMMUNOLOGY

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

(2009) S Mustjoki et al.   LEUKEMIA

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

Dasatinib in relapsed or plateau-phase multiple myeloma

(2009) Tanya M. Wildes et al.   LEUKEMIA & LYMPHOMA

Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis

(2008) Patricia Balsas et al.   BIOCHEMICAL PHARMACOLOGY

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

(2008) A. Zollinger et al.   BLOOD

Validation of PDGFR  and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

(2008) A. M. L. Coluccia et al.   BLOOD

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD

Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib

(2008) R. Weichsel et al.   CLINICAL CANCER RESEARCH

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

(2008) D. H. Kim et al.   HAEMATOLOGICA